For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Injectable medications originally developed for the treatment of diabetes are also effective for weight loss and have surged ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Semaglutide increased maximum walking distance by 13% compared ... extension for Ozempic based on the results of the STRIDE trial. A decision by the Food and Drug Administration is expected some time ...

Liraglutide, meanwhile, is a GLP-1 drug developed by Novo Nordisk, that lacks the weight loss qualities of semaglutide or tirzepatide. There appears to be one major drawback to HIMS' latest ...

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutideStudy will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2 ...

The Boston Celtics kick off a two-game homestand against the Miami Heat on Wednesday. Boston has won nine games in a row and is second (56-19) in the East. Meanwhile, the Heat are struggling in ...

The average percentage of body weight change from baseline (starting weight) to one year was: 5.1 percent with semaglutide 2.2 percent with liraglutide A 2022 study found the dose matters ...

is pleased to announce that dosing has begun as scheduled in its human study GLP-1-H25-5 (the "Study") that is comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide.

Lexaria Bioscience (LEXX) announced that dosing has begun as scheduled in its human study GLP-1-H25-5 that is comparing oral DehydraTECH-liraglutide ... to the oral semaglutide and injectable ...